Companies › Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology, Immunology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HW071021 | – | Phase 1 | Advanced Solid Tumors | Feb 2027 |
| HWS116 Injection | – | Phase 1 | Advanced Solid Tumors | Aug 2027 |
| HW201877 | – | Phase 1 | Healthy Participants | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07373457 | HW201877 | Phase 1 | Healthy Participants | Immunology | Mar 2026 |
| NCT06882135 | HW071021 | Phase 1 | Advanced Solid Tumors | Oncology | Feb 2027 |
| NCT07413328 | HWS116 Injection | Phase 1 | Advanced Solid Tumors | Oncology | Aug 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.